Clinical Trials Logo

Filter by:
NCT ID: NCT06117280 Completed - Energy Clinical Trials

Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus

Start date: July 18, 2023
Phase: N/A
Study type: Interventional

Research has shown that acute ingestion of Paraxanthine (1,7-dimethylxanthine, PXN) can enhance various markers of focus, including memory, reaction time, and attention in healthy adults. To assess these effects, this placebo-controlled crossover trial will compare the effects of 200 and 300mg of PXN to a placebo control. Participants will abstain from caffeine for 3 days, before taking the first test/placebo product for 3 consecutive days. Participants will complete questionnaires at 30, 60, 90, and 120 minutes after ingestion on Day 1 and Day 3 of ingestion. Participants will have a 3-day washout period before trialing the next test product/placebo.

NCT ID: NCT06116708 Completed - Clinical trials for B52 Pilot Fatigue and Comfort

Kalogon Pilot Fatigue and Comfort Study

Start date: October 10, 2023
Phase: N/A
Study type: Interventional

The goal of this experimental study is to compare 2 different seat cushions in B52 cockpit seats to see if they affect pilot fatigue and comfort. The main questions it aims to answer are: 1. Does the Kalogon AF Prototype seat cushion improve pilot comfort compared to the standard seat cushion? 2. Does the Kalogon AF Prototype seat cushion reduce pilot fatigue compared to the standard cushion? Participants will spend 8 hours in a simulated cockpit playing a flight simulator. They will fill out multiple questionnaires and take 2 attention/reaction time tests throughout the 8-hours.

NCT ID: NCT06114238 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe

Start date: September 16, 2021
Phase: Phase 1
Study type: Interventional

This Phase 1, single-center study will be conducted in an open-label, randomized, parallel design. Healthy male and female participants aged 18 to 65 years will receive a single dose of itepekimab subcutaneous (SC) administered by either a prefilled syringe (PFS) or an autoinjector (AI). Itepekimab will be administered by a trained healthcare professional (HCP). Female and male participants will have a body weight between 50.0 and 100.0 kg and body mass index (BMI) >18.5 and ≤30 kg/m2. Participants who satisfy the inclusion criteria will be randomized to one of the 2 study intervention groups: - Itepekimab administered via AI (test) - Itepekimab administered via PFS (reference) The randomization will be stratified by weight category (<70 kg, ≥70 to <80 kg and ≥80 kg) and injection site (abdomen, thigh, and arm). Study duration for each participant is up to approximately 162 days, including: - Screening period: up to 21 days - Institutionalization: 2 days including 1 treatment day (Day 1) - Follow-up period: 140 days (±5 days) - End of study (EOS): Day 141 (± 5 days)

NCT ID: NCT06113926 Completed - Pain, Acute Clinical Trials

Racial Discrimination, Pain, and the Buffering Influences of Acknowledgment

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Black young adults (aged 18-30; N = 92) were racially included (i.e., received the ball an equal number of times) or excluded (i.e., received the ball only once) by other White players in a ball-tossing computer game called Cyberball; White experimenters acknowledged the exclusion for half of the excluded participants. Participants completed a cold-pressor task twice to measure pain sensitivity (threshold, tolerance, and unpleasantness): immediately prior, and after the Cyberball (and acknowledgment) manipulation. Participants also completed a post-manipulation survey examining the psychological effects of racial exclusion and acknowledgment (i.e., psychological needs satisfaction, negative affect, control).

NCT ID: NCT06113575 Completed - Clinical trials for Major Depressive Disorder

Practical Application of Accelerated iTBS for MDD

Start date: November 23, 2022
Phase: N/A
Study type: Interventional

The goal of this observational study is to evaluate the feasibility and efficacy of accelerated iTBS in adults diagnosed with Major Depressive Disorder. The main question it aims to answer is: What is the efficacy and tolerability of an accelerated iTBS regimen without radiological imaging in adults who have been diagnosed with Major Depressive Disorder and experience treatment resistant symptoms? Participants will complete 36 iTBS treatments in an accelerated schedule over five days. They will also complete several clinical assessments throughout their enrollment to evaluate their depressive symptoms and response to treatment.

NCT ID: NCT06113406 Completed - Clinical trials for Evaluating a Brief Intervention

Evaluation of Virtual Reality in Hazmat Training

Start date: May 31, 2023
Phase: N/A
Study type: Interventional

Type of study: Two-group comparison. Main question it aims to answer: Does the use of virtual reality emergency scenarios provide a practical and effective tool to supplement traditional instructor-led training for first responder trainees? A. For the traditional hazmat response training group; Traditional training will be held in the classroom environment for 45 minutes in the form of a lecture, then the training session will be terminated. B. For VR hazmat response training group; After the traditional classroom session has ended, the participants will complete the additional VR training scenario, online content, and question-answer session. Once completed the session will be closed.

NCT ID: NCT06112912 Completed - Clinical trials for Components of REAL Essentials

Components Study of REAL Essentials

REA
Start date: January 1, 2022
Phase:
Study type: Observational

The Components Study of REAL Essentials (REA) is a descriptive implementation and outcome study. This study aims to identify the components that matter most for promoting positive health behaviors and outcomes among adolescents. The study will examine a variety of components to determine which are most influential in predicting participant outcomes. In addition, the study will measure youth engagement in programming from various perspectives and examine the role of engagement as an intermediary factor to achieving youth outcomes.

NCT ID: NCT06112782 Completed - Androgenic Alopecia Clinical Trials

Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia. This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office Keravive by Hydrafacial treatments at Day 0 and Weeks 4 and 8 in combination with daily application on Keravive Peptide Spray at home. Subjects will be assessed at Day 0, and Weeks 4, 8, and 20 by investigators using the Norwood Scale (males), Ludwig Classification (females), and a series of Likert scales for ranking improvement in scalp health and hair quality.

NCT ID: NCT06110494 Completed - Clinical trials for Apical Periodontitis

A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment

Start date: July 13, 2020
Phase: Phase 4
Study type: Interventional

The goal of this observational is study is to develop a protocol for root canal biofilms disinfection using a clinically approved and commercially available iron oxide nanoparticle formulation Ferumoxytol/H2O2 treatments. This protocol will be testing local single topical application of Ferumoxytol within the root canal system in patients going through routine root canal treatment, evaluate its potential as anti-biofilm treatment and compare it to the clinical gold standard disinfecting solution sodium hypochlorite (positive control) and saline (negative control).

NCT ID: NCT06109428 Completed - Analgesia Clinical Trials

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE

Start date: October 12, 2021
Phase: Phase 4
Study type: Interventional

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing abdominoplasty (Cohort 2).